secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001493152-23-040100
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ensysce Q3 net loss narrows to $2.7M; cash $1.5M; PF614 study results expected by year-end
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders was $2.7M ($0.87/share) vs $9.9M ($61.58) in Q3 2022.
- Cash and cash equivalents $1.5M as of Sep 30, 2023, down from $3.8M at June 30; post-quarter raised $1.7M in convertible notes.
- R&D expenses fell to $1.9M from $4.8M; G&A expenses fell to $1.2M from $1.7M.
- PF614-201 time-of-onset study results expected in December 2023; FDA End of Phase 2 meeting set for Jan 30, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223040100/0001493152-23-040100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315223040100/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer